Karimeldin Ma Salih1, Jalal Ali Bilal2, Widad Eldouch3, Ali Abdin4. 1. Associate Professor, Department of Pediatrics, College of Medicine, Bahri University , Sudan . 2. Assistant Professor, Department of Pediatrics, College of Medicine, Gasim University , KSA . 3. Pediatrician, Primary Health Care Department, MOH Sudan . 4. General Practitioner, MOH , Sudan .
Abstract
INTRODUCTION: Pneumonia is common presentation in the emergency room and is still a cause of morbidity and mortality. The rationale of this study was to test the trend of paediatricians to achieve rapid response facing severe pneumonia, the lack of agreed on plan for the management of community acquired pneumonia (CAP) and the few experiences regarding injectable form of β-lactam antimicrobial. MATERIALS AND METHODS: This is a prospective case control study, purposive randomized sampling, three patients were excluded since their information was incomplete, 132 patients were randomly divided into groups, one group named control group (penicillin according to the guidelines of WHO 2013), 33 patients; second group treated by β-lactam inhibitors (Augmentin IV) 50 patients; and third group treated by 3(rd) generation cephalosporin (ceftriaxone) 49 patients. The study was conducted at the main tertiary care and paediatrics teaching hospital in Khartoum capital of Sudan. The study was completed within the duration from 2010 to 2011. RESULTS: Both group showed more or less similar results regarding response, as well as the failure rate however, the Augmentin and ceftriaxone groups showed a little bit better survival than the control group. CONCLUSION:Antibiotics decrease the mortality rate among the pneumonia patients provided that it is given early in the disease.
RCT Entities:
INTRODUCTION:Pneumonia is common presentation in the emergency room and is still a cause of morbidity and mortality. The rationale of this study was to test the trend of paediatricians to achieve rapid response facing severe pneumonia, the lack of agreed on plan for the management of community acquired pneumonia (CAP) and the few experiences regarding injectable form of β-lactam antimicrobial. MATERIALS AND METHODS: This is a prospective case control study, purposive randomized sampling, three patients were excluded since their information was incomplete, 132 patients were randomly divided into groups, one group named control group (penicillin according to the guidelines of WHO 2013), 33 patients; second group treated by β-lactam inhibitors (Augmentin IV) 50 patients; and third group treated by 3(rd) generation cephalosporin (ceftriaxone) 49 patients. The study was conducted at the main tertiary care and paediatrics teaching hospital in Khartoum capital of Sudan. The study was completed within the duration from 2010 to 2011. RESULTS: Both group showed more or less similar results regarding response, as well as the failure rate however, the Augmentin and ceftriaxone groups showed a little bit better survival than the control group. CONCLUSION: Antibiotics decrease the mortality rate among the pneumoniapatients provided that it is given early in the disease.
Entities:
Keywords:
Augmentin; Ceftriaxone; Community acquired pneumonia; Empirical treatment
Authors: Michael Harris; Julia Clark; Nicky Coote; Penny Fletcher; Anthony Harnden; Michael McKean; Anne Thomson Journal: Thorax Date: 2011-10 Impact factor: 9.139
Authors: John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson Journal: Clin Infect Dis Date: 2011-10 Impact factor: 9.079
Authors: C D Schwigon; M Gabor; J Hartmann; R Mössinger; M Oberling; U Schubert; H Schwarck; M Springsklee; J Zinndorf Journal: Int J Antimicrob Agents Date: 1996-04 Impact factor: 5.283
Authors: Shams E Arifeen; D M Emdadul Hoque; Tasnima Akter; Muntasirur Rahman; Mohammad Enamul Hoque; Khadija Begum; Enayet K Chowdhury; Rasheda Khan; Lauren S Blum; Shakil Ahmed; M Altaf Hossain; Ashraf Siddik; Nazma Begum; Qazi Sadeq-ur Rahman; Twaha M Haque; Sk Masum Billah; Mainul Islam; Reza Ali Rumi; Erin Law; Z A Motin Al-Helal; Abdullah H Baqui; Joanna Schellenberg; Taghreed Adam; Lawrence H Moulton; Jean-Pierre Habicht; Robert W Scherpbier; Cesar G Victora; Jennifer Bryce; Robert E Black Journal: Lancet Date: 2009-08-01 Impact factor: 79.321